Trial
NCT00690846
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Wake Forest University Health Sciences
Collaborators
—
Condition
Pyoderma Gangrenosum
Intervention
adalimumab
Why stopped
Dr. Jorizzo has withdrawn from this study due to time it is taking to start
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-20